Rivaroxaban as effective as warfarin for left ventricular thrombus post-MI
ACC Action CenterRivaroxaban as effective as warfarin for left ventricular thrombus post-MI
Mobile integrated health program in patients with HF
ACC Action CenterMobile integrated health program in patients with HF
Phase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
ACC Action CenterPhase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
Low-dose apixaban noninferior to full dose in cancer-associated VTE
ACC Action CenterLow-dose apixaban noninferior to full dose in cancer-associated VTE
AI model may accelerate risk stratification of coronary revascularization in ED
ACC Action CenterAI model may accelerate risk stratification of coronary revascularization in ED
- 5 questions
Novel Transcatheter Solution Approved for Tricuspid Regurgitation
Medical Industry FeatureNovel Transcatheter Solution Approved for Tricuspid Regurgitation
Advancing Cardiology and Heart Surgery Through a History of Collaboration
Medical Industry FeatureAdvancing Cardiology and Heart Surgery Through a History of Collaboration
Aiming Lower: Addressing the Gaps in LDL-C Management for ASCVD Patients
Medical Industry FeatureAiming Lower: Addressing the Gaps in LDL-C Management for ASCVD Patients
CV Risk in Patients with Narcolepsy: See the Data
Medical Industry FeatureCV Risk in Patients with Narcolepsy: See the Data
From Symptoms to Diagnosis: Navigating ATTR Amyloidosis in Clinical Practice
Medical Industry FeatureFrom Symptoms to Diagnosis: Navigating ATTR Amyloidosis in Clinical Practice
Uncovering Unmet Needs in ATTR Amyloidosis
Medical Industry FeatureUncovering Unmet Needs in ATTR Amyloidosis
- 05/12/2025
- 05/09/2025
- 05/09/2025
- 05/08/2025
- 05/08/2025
- 05/08/2025